CClinicalTrials.gg
Not yet recruitingNCT07189000PREPARE-CANUpdated Sep 23, 2025

Patient-centered REhabilitation Program to Advance REcovery

An interventional study of App-based prehabilitation program and Usual care (ERAS-standard perioperative care) in Cancer, Frailty and Prehabilitation, sponsored by Korea University Anam Hospital. Not yet recruiting at 1 site in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2025-09-23.

Sponsored by Korea University Anam Hospital · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Study summary

The goal of this clinical trial is to learn whether an app-based, patient-centered prehabilitation program improves preoperative functional capacity in adults scheduled for elective cancer surgery. The main questions it aims to answer are:

Does the program increase the six-minute walk distance (6MWD) measured on the preoperative day (within 24-48 hours before surgery)?

Compared with usual care, does the program improve preoperative adherence to home 6MWT practice and patient-reported anxiety/depression (HADS)?

Researchers will compare an app-based prehabilitation program to usual care to see if the program improves preoperative functional capacity.

Participants will:

Use a study app to perform weekly home six-minute walk tests (6MWT) and complete brief daily check-ins (exercise, nutrition, psychological status) before surgery.

Attend routine preoperative admission (no extra visit) for in-hospital 6MWT (primary endpoint) and brief assessments (grip strength, Timed Up \& Go, HADS, skeletal muscle mass by InBody where available/fee-free).

Attend one routine postoperative outpatient visit at 3 or 6 months (site-standard timing) for follow-up assessments.

No additional study-specific clinic visits are required outside usual care.

Read the detailed description

Overview and Rationale This multicenter, pragmatic, parallel-group randomized trial evaluates a minimal-cost, app-based, patient-centered prehabilitation program for adults undergoing elective cancer surgery. The intervention focuses on home feasibility and adherence without additional clinic visits. The single prespecified primary endpoint is defined in the Outcome Measures module. Secondary measures are collected with low or no cost (research staff-administered functional tests, app surveys/logs, and fee-free body composition where available). The design reflects three principles: (i) patient self-management supported by simple digital tools, (ii) multimodal content (exercise, nutrition, psychological support), and (iii) streamlined follow-up aligned with routine care.

Study Design and Setting Randomized (1:1), parallel assignment, open-label; outcome assessors for in-hospital functional testing will be masked when feasible. Three university hospitals participate under a common SOP and centralized coordination. Total planned enrollment is 60 participants.

Interventions

App-based prehabilitation (Experimental): Participants receive access to a lightweight mobile/web app that provides weekly prompts to perform a home six-minute walk test (6MWT), brief daily check-ins (exercise performed, simple nutrition targets, mood/stress), push reminders, and basic guidance content. The app logs attempts, completion, and distance input (or pedometer/GPS-assisted estimate when available) and allows secure CSV export for analysis.

Usual care (Control): Standard perioperative education and care per site ERAS practice; no study app.

No additional study-specific clinic visits are required. All on-site assessments are scheduled to coincide with routine preoperative admission and one routine postoperative outpatient visit (either \~3 or \~6 months, unified across sites).

Assessment Schedule (condensed, aligned to routine care)

Remote preoperative phase: Weekly home 6MWT and daily check-ins via the app until surgery (participants receive standardized instructions and safety prompts within the app).

Preoperative day (in hospital): Standardized in-hospital 6MWT on a measured indoor course; research staff administer grip strength using a calibrated hand dynamometer and the Timed Up \& Go (TUG); Hospital Anxiety and Depression Scale (HADS) via app or paper; skeletal muscle mass by bioimpedance (InBody) only through fee-free pathways available at the site.

One routine postoperative outpatient visit (3 or 6 months): Grip, TUG, HADS, and fee-free InBody (if available).

Postoperative clinical outcomes (e.g., complications within 30 days, length of stay, readmission) are abstracted from the electronic health record per SOP.

Home 6MWT Operating Procedure (app-assisted, summary) Participants are guided to use a flat corridor/sidewalk with markers (e.g., 20-30 m). The app provides standardized instructions (based on ATS principles), a safety checklist (stop for chest pain, severe dyspnea, presyncope), and validity checks (continuous 6 minutes, pause limits, outlier flags). If equipped, step counter or GPS assists distance estimation; otherwise, distance is calculated from marked laps. Adherence (attempts/week, completion %) is automatically captured.

Randomization and Allocation Concealment A centralized, site-stratified, permuted-block sequence is generated by the coordinating center. Allocation is revealed after baseline registration and app onboarding. Because the behavioral nature precludes participant blinding, efforts are made to blind in-hospital outcome assessors (separate staff, standardized scripts, identical test setup).

Data Capture and Management App data are stored under a study ID (no direct identifiers in the app database). On-site measures are entered into an eCRF (secure spreadsheet/EDC with audit trail). Data are backed up on institutional servers with access restricted to authorized study staff. Deidentified analysis datasets are created after data lock. Data retention follows institutional policy and IRB requirements.

Safety and Monitoring Risk is minimal (submaximal walking test and questionnaires). The app includes safety messaging and an emergency stop prompt. Adverse events (AEs) related to testing are recorded; serious AEs are reported per site IRB timelines. A formal independent DMC is not planned due to minimal risk; oversight is provided by the PI and site PIs with periodic monitoring meetings, protocol adherence checks, and query resolution.

Quality Assurance All sites undergo initiation with training on: standardized 6MWT course setup, dynamometer calibration and grip testing posture, TUG instructions/timing, and uniform HADS administration. Checklists are used for each assessment session. The coordinating center performs routine data quality reviews and cross-site consistency checks.

Statistical Considerations (brief) Analyses will follow the intention-to-treat principle. For the prespecified primary endpoint (defined in the Outcome Measures module), between-group comparison will use linear models with adjustment for key covariates (e.g., age, sex, site, surgical category, baseline activity). Secondary outcomes include app-logged adherence, HADS, grip, TUG, fee-free body composition (where available), and postoperative clinical endpoints; these will be analyzed using appropriate generalized linear models. Sensitivity analyses will explore per-protocol effects (e.g., predefined app adherence thresholds). Missing data will be addressed using multiple imputation or model-based methods as appropriate. With 60 participants, the study is powered primarily for feasibility and to estimate effect sizes with reasonable precision to inform future scaling.

Confidentiality and Privacy Only coded study IDs appear in analytical datasets. Contact details are stored separately at the site level. App content avoids collecting unnecessary identifiers. Data transmission uses encrypted channels; access is role-based and logged.

Dissemination Results will be submitted to peer-reviewed journals and scientific meetings. Summary results will be posted on the registry per applicable policies. If effective and feasible, the program is intended to inform broader implementation within ERAS pathways and future larger trials.

Limitations and Mitigation As an open-label behavioral intervention with app logging, performance bias is possible; assessor masking and standardized protocols aim to reduce measurement bias. Fee-free availability of bioimpedance may vary by site; these measures are secondary/exploratory and analyzed accordingly. The design prioritizes feasibility and scalability while preserving rigorous, prespecified endpoints.

02

Conditions studied

  • Cancer
  • Frailty
  • Prehabilitation

Keywords

  • prehabilitation
  • frailty
  • cancer
03

In context

Neoplasms

9,359 studies on the registry are indexed under Neoplasms; 2,486 are open to participants now.

This study's planned enrollment of 60 is above the median of 50 across 7,250 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Korea University Anam Hospital is the lead sponsor of 110 studies on the registry; 29 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Adults ≥18 years.
  • Elective cancer surgery planned under general anesthesia at a participating site (e.g., gastrointestinal, hepatobiliary-pancreatic, thoracic, gynecologic, or other site-approved cancer operations).
  • Ambulatory: able to walk independently (assistive device such as a cane is allowed) and deemed safe to perform a six-minute walk test (6MWT) per investigator judgment.
  • Smartphone access and app use: owns/has regular access to a smartphone capable of running the study app and agrees to use the app (notifications, weekly home 6MWT logging, brief daily check-ins).
  • Preoperative lead-in: expected interval of ≈14 days or more between consent/randomization and surgery to allow prehabilitation exposure (shorter intervals may be screened but must allow minimum onboarding and at least one home 6MWT).
  • Able to understand study procedures and provide written informed consent (Korean or English literacy sufficient to follow app instructions).

Exclusion criteria

Exclusion Criteria:

  • Emergency surgery or surgery date that cannot accommodate even minimal prehabilitation onboarding.
  • ASA IV or higher, or any unstable/critical condition that, in the investigator's opinion, makes participation unsafe.
  • Contraindications to 6MWT/light walking, including but not limited to: unstable angina, recent myocardial infarction (≤30 days), decompensated heart failure, uncontrolled clinically significant arrhythmia, severe symptomatic aortic stenosis, severe uncontrolled pulmonary disease, or investigator-judged safety concerns (e.g., resting severe hypoxemia, high fall risk).
  • Non-ambulatory status or musculoskeletal/neurologic conditions that preclude performing a 6MWT.
  • Cognitive impairment or psychiatric/behavioral conditions that preclude informed consent or reliable app use.
  • Inability or unwillingness to install/use the study app (or lack of regular smartphone access).
  • Concurrent enrollment in another interventional clinical trial that would confound outcomes or burden participants (per investigator judgment).
  • Any other medical or logistical condition that, in the opinion of the investigator, would interfere with protocol adherence, outcome assessment on the preoperative day, or the routine postoperative follow-up visit.
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    RH group

    Participants receive an app-based, patient-centered prehabilitation program from randomization until surgery (no extra clinic visits). The program includes weekly home six-minute walk tests (6MWT) logged in the app, brief daily check-ins (exercise performed, simple nutrition targets, mood/stress), push reminders, and short educational video/handout content. Safety prompts and validity checks (continuous 6 minutes, pause limits, outlier flags) are embedded in the app. All on-site assessments are aligned with routine care: preoperative-day in-hospital testing (primary 6MWD, plus grip/TUG/HADS; InBody via fee-free pathway where available) and one routine postoperative outpatient visit (3 or 6 months; site-standard) for follow-up secondary measures. Usual perioperative care is provided per site ERAS practice.

    Behavioral: App-based prehabilitation program

  • Active comparator
    UC group

    Participants receive standard perioperative care per each site's ERAS-consistent routine (preoperative counseling/education, routine mobilization). No study app is provided and no remote 6MWT logging is required. For outcomes collection only, participants undergo the same preoperative-day in-hospital assessment (primary 6MWD, plus grip/TUG/HADS; InBody via fee-free pathway where available) and one routine postoperative outpatient visit (3 or 6 months; site-standard). No additional study-specific clinic visits are required.

    Other: Usual care (ERAS-standard perioperative care)

Interventions

  • BehavioralApp-based prehabilitation program

    A lightweight mobile/web application delivering a patient-centered prehabilitation program from randomization until surgery. Features include: weekly home six-minute walk tests (6MWT) logged in the app; brief daily check-ins for exercise performed, simple nutrition targets, and mood/stress; push reminders; short educational video/handout content; and CSV export for analysis. The app provides standardized instructions and safety prompts for the home 6MWT and basic validity checks (continuous 6 minutes, pause limits, outlier flags). No additional study-specific clinic visits are required beyond routine preoperative admission and one routine postoperative outpatient visit.

  • OtherUsual care (ERAS-standard perioperative care)

    Standard perioperative counseling/education and routine mobilization per institutional ERAS practice. No study app is provided and no remote 6MWT logging is required. Outcome assessments are collected at routine preoperative admission (including in-hospital 6MWT per protocol) and at one routine postoperative outpatient visit (≈3 or 6 months per unified site policy). No additional study-specific clinic visits are required.

06

What researchers measure

Primary outcomes

  1. Six-Minute Walk Distance (6MWD)

    Distance in meters covered during a standardized six-minute walk test (6MWT) performed in hospital on the preoperative day. Testing follows ATS-aligned instructions on a marked indoor course (\~30 m). Trained staff administer the test and are blinded to group allocation when feasible. The primary endpoint is the absolute distance (meters) on the preoperative day; baseline/home 6MWT collected via the app may be used as a covariate but is not part of the primary measure. Safety prompts (stop for chest pain, severe dyspnea, presyncope) are embedded in the SOP.

    Time frame: Preoperative day (within 24-48 hours before surgery)

Secondary outcomes

  1. Hospital Anxiety and Depression Scale (HADS), change

    Change in total HADS score (0-42) from the preoperative day (in-hospital assessment) to the routine postoperative outpatient visit.

    Time frame: Preoperative day (within 24-48 hours before surgery)

  2. Grip strength, change

    Change in maximal hand-grip strength measured with a calibrated dynamometer by trained research staff. Dominant hand is preferred; highest of three trials recorded at each time point.

    Time frame: Preoperative day (within 24-48 hours before surgery)

  3. Timed Up & Go (TUG), change

    Change in time to stand from a chair, walk 3 m, turn, return, and sit. Standardized instructions; best of two trials recorded.

    Time frame: Preoperative day (within 24-48 hours before surgery)

  4. Skeletal muscle mass index (SMI), change

    Change in SMI by bioimpedance analysis (InBody) obtained only via fee-free pathways available at each site; exploratory where not available.

    Time frame: Preoperative day (within 24-48 hours before surgery)

  5. App-logged home 6MWT adherence (preoperative period)

    Percentage of weeks with ≥1 valid home 6-minute walk test (6MWT) logged in the app, per participant, averaged across participants. Validity checks per SOP (continuous 6 minutes, pause limits, outlier flags).

    Time frame: From enrollment to preoperative day (1 day before surgery)

  6. Postoperative complications within 30 days

    Number of participants with ≥1 complication graded Clavien-Dindo II or higher, abstracted from the electronic health record per SOP.

    Time frame: postoperative day 30

  7. hospital length of stay

    Duration of the index surgical admission.

    Time frame: through study completion, an average of 1 year

  8. 30-day readmission

    Number of participants with all-cause readmission within 30 days of the index discharge.

    Time frame: postoperative day 30

Other outcomes

  1. App daily check-in completion (preoperative period)

    Percentage of preoperative days with any completed daily check-in (exercise). Averaged across participants.

    Time frame: From enrollment to preoperative day (1 day before surgery)

07

Study locations

1 site
  • Korea University Anam Hospital
    Seoul, South Korea
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07189000
Lead sponsor
Korea University Anam Hospital
Responsible party
Eunji Ko (Clinical Assistant Professor, Korea University Anam Hospital) — Principal investigator
First posted
Sep 23, 2025
Start date
Jan 1, 2026 (estimated)
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Sep 23, 2025

Study contacts

Eunji Ko, M.D., Ph.D.
Contact
froken.ko@gmail.com
+82-10-3423-8249

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion